DNAPrint Genomics, Inc. (DNAG) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
DNAPrint Genomics, Inc. (DNAG) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. La acción obtiene una puntuación de 61/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 18 mar 2026DNAPrint Genomics, Inc. (DNAG) Resumen de Asistencia Médica y Tuberías
DNAPrint Genomics, Inc. specializes in genetic testing products and services, offering ancestry analysis, forensic DNA tools, and genotyping systems. With a focus on serving forensic science, genealogical research, and pharmaceutical development clients, the company operates in the competitive biotechnology sector, marked by rapid innovation and evolving regulatory landscapes.
Tesis de Inversión
DNAPrint Genomics, Inc. operates in the niche market of genetic testing with products like AncestryByDNA and DNAWitness. The company's gross margin of 31.0% indicates potential for profitability if sales increase. However, the negative P/E ratio and a profit margin of -507.5% highlight significant financial challenges. Growth catalysts include expanding applications of RETINOME in forensics and increased adoption of GenomeLab SNPstream Genotyping System. Key risks involve the company's ability to achieve profitability and manage its operational costs. The high beta of 1.53 suggests the stock is more volatile than the market, adding a layer of risk for investors. Success hinges on effective commercialization and strategic partnerships.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Gross Margin of 31.0% indicates potential for profitability with increased sales volume.
- Profit Margin of -507.5% reflects significant operational losses and the need for improved cost management.
- Beta of 1.53 suggests higher volatility compared to the overall market, indicating a riskier investment.
- Market Cap of $0.00B indicates the company is a micro-cap stock with limited liquidity.
- The company serves diverse sectors including forensic science, genealogical research, consumer products, and pharmaceutical development, providing multiple revenue streams.
Competidores y Pares
Fortalezas
- Specialized genetic testing products and services.
- Expertise in ancestry analysis and forensic DNA tools.
- Diverse customer base across multiple sectors.
- Proprietary technologies like RETINOME and GenomeLab SNPstream.
Debilidades
- Negative profit margin and financial losses.
- Limited market capitalization and liquidity.
- Dependence on niche markets.
- Unknown disclosure status on the OTC market.
Catalizadores
- Upcoming: Potential partnerships with pharmaceutical companies for personalized medicine initiatives.
- Ongoing: Continued development and refinement of RETINOME technology for forensic applications.
- Ongoing: Expansion of direct-to-consumer genetic testing services.
- Upcoming: Potential for increased adoption of GenomeLab SNPstream Genotyping System in research institutions.
Riesgos
- Ongoing: Negative profit margin and financial losses impacting long-term sustainability.
- Potential: Intense competition in the biotechnology industry.
- Potential: Stringent regulatory requirements and compliance costs.
- Potential: Technological obsolescence of existing products.
- Ongoing: Limited market capitalization and liquidity on the OTC market.
Oportunidades de crecimiento
- Expansion of RETINOME Applications in Forensics: DNAPrint Genomics can expand the application of its RETINOME technology in forensic science. The market for forensic DNA analysis is projected to reach $6.1 billion by 2028, growing at a CAGR of 11.2% from 2021. By enhancing the accuracy and capabilities of RETINOME, DNAPrint Genomics can capture a larger share of this market, providing law enforcement agencies with advanced tools for identifying suspects and solving crimes. This expansion requires strategic partnerships with forensic laboratories and continuous innovation in DNA phenotyping technologies.
- Increased Adoption of GenomeLab SNPstream Genotyping System: The GenomeLab SNPstream Genotyping System offers high genotyping rates and efficient data generation, positioning it as a valuable tool for pharmaceutical development and research. The global genotyping market is expected to reach $12.5 billion by 2027. DNAPrint Genomics can drive adoption by targeting research institutions, pharmaceutical companies, and diagnostic labs. Demonstrating the system's cost-effectiveness and superior performance through case studies and collaborations will be crucial for market penetration.
- Strategic Partnerships in Pharmaceutical Development: DNAPrint Genomics can leverage its expertise in genetic testing to form strategic partnerships with pharmaceutical companies. The pharmaceutical industry increasingly relies on genetic data to develop personalized medicine and targeted therapies. By offering customized genotyping services and ancestry analysis, DNAPrint Genomics can support drug discovery and clinical trials. These partnerships can provide a stable revenue stream and enhance the company's reputation in the pharmaceutical sector. The personalized medicine market is projected to reach $2.4 trillion by 2030.
- Direct-to-Consumer Genetic Testing Expansion: DNAPrint Genomics can expand its direct-to-consumer (DTC) genetic testing services, focusing on ancestry analysis and personalized health insights. The DTC genetic testing market is growing, driven by increasing consumer interest in understanding their genetic heritage and health predispositions. By offering user-friendly testing kits and comprehensive reports, DNAPrint Genomics can attract a broader customer base. Marketing efforts should emphasize the accuracy and reliability of the company's testing methods, differentiating it from competitors in the crowded DTC market. The global DTC genetic testing market is expected to reach $6.2 billion by 2027.
- Geographic Expansion into Emerging Markets: DNAPrint Genomics can pursue geographic expansion into emerging markets, where demand for genetic testing services is growing. Countries in Asia-Pacific and Latin America are experiencing increased investment in healthcare infrastructure and research. By establishing partnerships with local distributors and laboratories, DNAPrint Genomics can access these markets and offer its genetic testing products and services to a new customer base. Adapting its products to meet the specific needs and regulatory requirements of each market will be essential for successful expansion.
Oportunidades
- Expansion of RETINOME applications in forensics.
- Increased adoption of GenomeLab SNPstream in pharmaceutical development.
- Strategic partnerships with pharmaceutical companies.
- Growth in direct-to-consumer genetic testing market.
Amenazas
- Intense competition in the biotechnology industry.
- Stringent regulatory requirements and compliance costs.
- Potential for technological obsolescence.
- Economic downturn affecting consumer spending and research budgets.
Ventajas competitivas
- Proprietary genetic testing technologies and assays.
- Expertise in forensic DNA analysis and phenotyping.
- Established relationships with forensic science and research institutions.
- Diverse product portfolio catering to multiple market segments.
Acerca de DNAG
DNAPrint Genomics, Inc., originally incorporated as Lexington Energy, Inc. in 1983, is a biotechnology company based in Sarasota, Florida, with a subsidiary in Leverkusen, Germany. The company develops and markets genetic testing products and services, catering to a diverse clientele across forensic science, genealogical research, consumer products, and pharmaceutical development. Its product portfolio includes AncestryByDNA, a pan-chromosomal assay for genetic ancestry; EurasianDNA, which measures European sub-ancestry; and EuropeanDNA, which reports a customer's proportional basic continental European ancestry. DNAPrint Genomics also offers DNAWitness, a tool used to determine genetic heritage from DNA samples obtained from crime scenes, and RETINOME, which provides a physical portrait of a person of interest based on a DNA sample. Additionally, RETINOME allows for inferring eye color from DNA. The company's GenomeLab SNPstream Genotyping System provides genotyping rates, utilizing a multiplexing format to generate data with minimal reagents. DNAPrint Genomics's focus on specialized genetic testing solutions positions it within a niche segment of the broader biotechnology market, emphasizing innovation and application across multiple sectors.
Qué hacen
- Develops and markets genetic testing products and services.
- Offers AncestryByDNA, a pan-chromosomal assay for genetic ancestry.
- Provides EurasianDNA, which measures European sub-ancestry.
- Offers EuropeanDNA, which reports proportional basic continental European ancestry.
- Provides DNAWitness to determine genetic heritage from crime scene DNA samples.
- Offers RETINOME, which provides a physical portrait based on DNA samples.
- Offers RETINOME, which allows inferring eye color from DNA.
- Provides GenomeLab SNPstream Genotyping System for genotyping.
Modelo de Negocio
- Sales of genetic testing kits and services to consumers for ancestry analysis.
- Providing forensic DNA analysis tools and services to law enforcement agencies.
- Offering genotyping services and systems to pharmaceutical companies and research institutions.
- Generating revenue through strategic partnerships and collaborations in the healthcare sector.
Contexto de la Industria
DNAPrint Genomics, Inc. operates within the biotechnology industry, a sector characterized by rapid innovation, intense competition, and stringent regulatory oversight. The genetic testing market is experiencing growth, driven by advancements in technology and increasing demand for personalized medicine and ancestry services. DNAPrint Genomics competes with companies offering similar genetic testing services, including ancestry analysis and forensic DNA tools. The company's success depends on its ability to differentiate its products, navigate regulatory hurdles, and establish strategic partnerships within the evolving landscape.
Clientes Clave
- Individuals interested in ancestry and genealogy research.
- Law enforcement agencies and forensic laboratories.
- Pharmaceutical companies involved in drug discovery and clinical trials.
- Research institutions conducting genetic studies.
- Consumer product companies utilizing genetic data for product development.
Finanzas
Gráfico e información
Precio de la acción de DNAPrint Genomics, Inc. (DNAG): Price data unavailable
Últimas noticias
-
New 52-Week Lows For Monday Morning
· 5 ago 2019
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para DNAG.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para DNAG.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de DNAG en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Jatin Patel
CEO
Jatin Patel serves as the CEO of DNAPrint Genomics, Inc., managing a team of 24 employees. Information regarding Mr. Patel's detailed career history, educational background, and previous roles is not available in the provided data. His leadership is focused on guiding the company's strategic direction in the competitive biotechnology sector, emphasizing innovation and market expansion.
Historial: Due to the limited information available, specific achievements, strategic decisions, and company milestones under Jatin Patel's leadership cannot be detailed. His tenure is marked by the ongoing development and marketing of genetic testing products and services, with a focus on serving forensic science, genealogical research, consumer products, and pharmaceutical development clients.
Información del mercado OTC de DNAG
The OTC Other tier represents the lowest tier of the OTC market, indicating that DNAPrint Genomics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be subject to greater risks due to less stringent regulatory oversight. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies do not have to adhere to the same listing standards, potentially increasing the risk for investors.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited Financial Disclosure: The unknown disclosure status increases the risk of investing in DNAG, as investors may lack access to crucial financial information.
- Low Liquidity: As an OTC Other stock, DNAG likely has low trading volume, making it difficult to buy or sell shares efficiently.
- Regulatory Scrutiny: OTC stocks are subject to less regulatory oversight, increasing the potential for fraud or mismanagement.
- Price Volatility: The combination of low liquidity and limited disclosure can lead to significant price swings.
- Going Concern Risk: Companies in the OTC Other tier may face a higher risk of financial distress or bankruptcy.
- Verify the company's financial statements and SEC filings, if available.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Determine the company's revenue sources and profitability.
- Investigate any legal or regulatory issues involving the company.
- Consult with a financial advisor to assess the risks and potential rewards.
- Check for any news or press releases about the company's performance.
- Longevity in the market since incorporation in 1983.
- Development of specialized genetic testing products.
- Serving diverse sectors including forensic science and pharmaceutical development.
- Subsidiary in Leverkusen, Germany, indicating international presence.
DNAG Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar DNAG?
DNAPrint Genomics, Inc. (DNAG) actualmente tiene una puntuación IA de 61/100, indicando puntuación moderada. Fortaleza clave: Specialized genetic testing products and services.. Riesgo principal a monitorear: Ongoing: Negative profit margin and financial losses impacting long-term sustainability.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de DNAG?
DNAG actualmente puntúa 61/100 (Grado B) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de DNAG?
Los precios de DNAG se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre DNAG?
La cobertura de analistas para DNAG incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en DNAG?
Las categorías de riesgo para DNAG incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Negative profit margin and financial losses impacting long-term sustainability.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de DNAG?
La relación P/E para DNAG compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está DNAG sobrevalorada o infravalorada?
Determinar si DNAPrint Genomics, Inc. (DNAG) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de DNAG?
DNAPrint Genomics, Inc. (DNAG) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited financial data available for DNAPrint Genomics, Inc.
- OTC market stocks are inherently more risky than exchange-listed stocks.
- AI analysis pending, indicating further insights may be available in the future.